Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $12.003 million which beat the analyst consensus estimate of $10.500 million by 14.31 percent. This is a 32.92 percent increase over sales of $9.030 million the same period last year.